Cytokinetics announces receipt of breakthrough therapy designation from FDA for aficamten

Cytokinetics

9 December 2021 - FDA granted designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy Based on results of REDWOOD-HCM.

Cytokinetics today announced that the U.S. FDA has granted breakthrough therapy designation for aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Aficamten is a next generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy.

Read Cytokinetics press release

Michael Wonder

Posted by:

Michael Wonder